Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: A systematic review

Rheumatology (United Kingdom)

Volumn 54, Issue 11, 2015, Pages 2042-2050

  Rodríguez García, Veronica ^a   Ioannou, Yiannis ^b,c   Fernández Nebro, Antonio ^a   Isenberg, David A ^b   Giles, Ian P ^b  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b Rayne Institute   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anti phospholipid antibodies; Anti phospholipid syndrome; New assays; Non criteria

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; BINDING PROTEIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOCORTIN 5; PHOSPHOLIPID ANTIBODY;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ASSAY; ATHEROSCLEROSIS; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BINDING ASSAY; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC VALUE; EMBASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDLINE; MONONUCLEOSIS; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PREGNANCY DISORDER; PRIORITY JOURNAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; SAMPLE SIZE; SPECTROFLUOROMETRY; SYPHILIS; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

EID: 84946736351     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev226     Document Type: Article

References (36)

1. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013;122:817-24.
3. Pengo V, Biasiolo A, Pegoraro C et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005;93:1147-52.
4. Tincani A, Andreoli L, Casu C, Cattaneo R, Meroni P. Antiphospholipid antibody profile: implications for the evaluation and management of patients. Lupus 2010;19:432-5.
5. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
6. Bertolaccini ML, Amengual O, Atsumi T et al. ''Non-criteria'' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus 2011;20:191-205.
7. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
8. Alarcón-Segovia D, Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992;21:275-86.
9. 2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol 2001;185:748-53.
10. 2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol 1999;117:574-9.
11. 2-GPI. J Autoimmun 2006;27:266-71.
12. De Laat B, Pengo V, Pabinger I et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009;7:1767-73.
13. Hunt BJ, Wu X-X, de Laat B et al. Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome. Am J Obstet Gynecol 2011;205:485.e17-23.
14. 2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile? Ann Rheum Dis 2011;70:380-3.
15. Wu X-X, Pierangeli SS, Rand JH. Resistance to annexin A5 binding and anticoagulant activity in plasmas from patients with the antiphospholipid syndrome but not with syphilis. J Thromb Haemost 2006;4:271-3.
16. Rand JH, Wu X-X, Lapinski R et al. Detection of antibodymediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004;104:2783-90.
17. Bertolaccini ML, Roch B, Amengual O et al. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. Br J Rheumatol 1998;37:1229-32.
18. Branch DW, Silver R, Pierangeli S, van Leeuwen I, Harris EN. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol 1997;89:549-55.
19. Sanmarco M, Gayet S, Alessi M-C et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost 2007;97:949-54.
20. Donohoe S, MacKie IJ, Isenberg D, Machin SJ. Antiprothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol 2001;113:544-9.
21. Atsumi T, Ieko M, Bertolaccini ML et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982-93.
22. Guerin J, Smith O, White B et al. Antibodies to prothrombin in antiphospholipid syndrome and inflammatory disorders. Br J Haematol 1998;102:896-902.
23. Muñoz-Rodríguez FJ, Reverter JC, Font J et al. Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. Haematologica 2000;85:632-7.
24. Ortona E, Capozzi A, Colasanti T et al. Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood 2010;116:2960-7.
25. Pericleous C, Ruiz-Limón P, Romay-Penabad Z. Affinitypurified antibodies directed to domain I of beta 2GPI are pathogenic in a mouse model of thrombosis. Rheumatology 2013;52 (Suppl 1): i131 (Abstract 199).
26. 2-glycoprotein I and its interaction with human monoclonal antibodies. Mol Immunol 2011;49:56-63.
27. Pierangeli SS, Liu X, Espinola R et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000;84:388-95.
28. Giles I, Pericleous C, Liu X et al. Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. J Immunol 2009;182:4836-43.
29. 2-glycoprotein I: proof of concept. J Thromb Haemost 2009;7:833-42.
30. 2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 2014;123:3478-87.
31. 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005;105:1540-5.
32. Pericleous, C, Garza-Garcia, A, Murfitt, L. Profiling sub-types of anti-beta 2 glycoprotein i and anti-domain i antibodies may distinguish between different clinical phenotypes of the antiphospholipid syndrome. Arthritis Rheum 2011;63:S9.
33. 2 glycoprotein I antibodies. Curr Rheumatol Rep 2013;15:343.
34. 2-glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 2013;65:3186-93.
35. Rand JH, Wu X-X, Quinn AS, Taatjes DJ. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 2010;19:460-9.
36. Rand JH, Wu X-X, Quinn AS et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010;115:2292-9.